• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

Pegylated erythropoietin and darbepoetin Alfa: A study on comparison of renal parameters among CKD patients on maintenance hemodialysis

    Dr.Raghu Nandan,Dr.Anil Kumar,Dr.Vinay Durgad

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 301-307

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Chronic inflammation is a common feature of CKD and is a major cause of its associated
morbidity and mortality. Erythropoiesis is inhibited by several pro-inflammatory cytokines
such as interleukin-1, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ).12
These cytokines are particularly involved in the inflammatory process as they are directly
produced by macrophages (TNF-α, IL-1) or because their production by another cell is
induced by a macrophage cytokine (IFN-γ). Several studies have shown that markers of
inflammation are associated with a decreased response to erythropoietin. Out of these 52
patients, 12 patients couldn’t complete the study. 5 patients (2 in group A and 3 in group B)
left the study in between due to some unknown causes and 7 patients (4 in group A and 3 in
group B) expired during the study.So finally 40 patients (20 in each group) completed the
study. In group A there was a slight decrease in systolic and diastolic blood pressure from
baseline values of 153.5±12.06 and 92.3±6.06 mm of Hg to 150.4±12.62 and 89.2±5.36 mm
of Hg at 3 months, but the decrease was not significant statistically (p >0.05). In group B also
there was a slight decrease in systolic and diastolic blood pressure from baseline values of
156.2±8.72 and 92.4±6.31 mm of Hg to 149.1±18.20 and 93.6±4.75 mm of Hg at 3 months,
but the decrease was not significant statistically (p >0.05).
Keywords:
    Pegylated erythropoietin darbepoetin alfa CKD
  • PDF (294 K)
  • XML
(2022). Pegylated erythropoietin and darbepoetin Alfa: A study on comparison of renal parameters among CKD patients on maintenance hemodialysis. European Journal of Molecular & Clinical Medicine, 9(1), 301-307.
Dr.Raghu Nandan,Dr.Anil Kumar,Dr.Vinay Durgad. "Pegylated erythropoietin and darbepoetin Alfa: A study on comparison of renal parameters among CKD patients on maintenance hemodialysis". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 301-307.
(2022). 'Pegylated erythropoietin and darbepoetin Alfa: A study on comparison of renal parameters among CKD patients on maintenance hemodialysis', European Journal of Molecular & Clinical Medicine, 9(1), pp. 301-307.
Pegylated erythropoietin and darbepoetin Alfa: A study on comparison of renal parameters among CKD patients on maintenance hemodialysis. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 301-307.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 118
  • PDF Download: 139
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus